Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept

Journal of Rheumatology

Volumn 35, Issue 4, 2008, Pages 662-667

  Boonen, Annelies ^a   Patel, Vaishali ^b   Traina, Shana ^b   Chiou, Chiun Fang ^b   Maetzel, Andreas ^b   Tsuji, Wayne ^b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b AMGEN INC   (United States)

Author keywords

Ankylosing spondylitis; Etanercept; Health resource utilization; Health related quality of life; Utility

Indexed keywords

ETANERCEPT; PLACEBO;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; OPEN STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SHORT FORM 36; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ADULT; ANTIRHEUMATIC AGENTS; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 41849104176     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing Spondylitis: an overview. Ann Rheum Dis 2002;61 Suppl 3:iii8-18.
2. van der Linden S, van der Heijde D, Braun J. Ankylosing Spondylitis. In: Harris EJ, Budd R, Firestein GS, Genovese MC, Sergent JS, Sledge CB, editors. Kelly's textbook of rheumatology. 7th ed. Philadelphia: Elsevier Saunders; 2005:1125-41.
3. Khan MA. Update on spondyloarthropathies. Ann Intern Med 2002;136:896-907.
4. Davis JC, van der Heijde D, Dougados M, Woolley JM. Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy. Arthritis Rheum 2005;53:494-501.
5. Ozgul A, Peker F, Taskaynatan MA, Tan AK, Dincer K, Kalyon TA. Effect of ankylosing spondylitis on health-related quality of life and different aspects of social life in young patients. Clin Rheumatol 2006;25:168-74.
6. Dagfinrud H, Mengshoel AM, Hagen KB, Loge JH, Kvien TK. Health status of patients with ankylosing spondylitis: a comparison with the general population. Ann Rheum Dis 2004;63:1605-10.
7. Zink A, Listing J, Klindworth C, Zeidler H. The national database of the German Collaborative Arthritis Centres: I. Structure, aims, and patients. Ann Rheum Dis 2001;60:199-206.
8. Boonen A, Chorus A, Miedema H, van der Heijde D, van der Tempel H, van der Linden S. Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis 2001;60:353-8.
9. Boonen A, van der Heijde D, Landewe R, et al. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis 2002;61:429-37.
10. Ward MM. Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res 1999;12:247-55.
11. Kobelt G, Andlin-Sobocki P, Maksymowych WP. Costs and quality of life of patients with ankylosing spondylitis in Canada. J Rheumatol 2006;33:289-95.
12. Kobelt G, Andlin-Sobocki P, Brophy S, Jonsson L, Calin A, Braun J. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). Rheumatology Oxford 2004;43:1158-66.
13. Drummond MF, O'Brien B, Stoddart G, Torrence G. Chapter 6: Cost-utility analysis. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford, New York: Oxford University Press; 1997:139-204.
14. Brooks R. EuroQOL: the current state of play. Health Policy 1996;37:53-72.
15. Hurst NP, Jobanputra P, Hunter M, Lambert M, Lochhead A, Brown H. Validity of EuroQOL - a generic health status instrument - in patients with rheumatoid arthritis. Economic and Health Outcomes Research Group. Br J Rheumatol 1994;33:655-62.
16. Boonen A, van der Heijde D, Landewe R, et al. How do the EQ-5D, SF-6D and well-being rating scale compare in patients with ankylosing spondylitis. Ann Rheum Dis 2007;66:771-7. Epub 2007 Jan 9
17. Brazier J, Usherwood T, Harper R, Thomas K. Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol 1998;51:1115-28.
18. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002;21:271-92.
19. Davis JC, Jr, van der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6.
20. Davis JC, van der Heijde DM, Braun J, et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 2005;64:1557-62.
21. Gorman JD, Sack KE, Davis JC, Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002;346:1349-56.
22. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
23. Kosinski M, Keller SD, Hatoum HT, Kong SX, Ware JE Jr. The SF-36 Health Survey as a generic outcome measure in clinical trials of patients with osteoarthritis and rheumatoid arthritis: tests of data quality, scaling assumptions and score reliability. Med Care 1999;37 Suppl:MS10-MS22.
24. Kosinski M, Keller SD, Ware JE, Jr, Hatoum HT, Kong SX. The SF-36 Health Survey as a generic outcome measure in clinical trials of patients with osteoarthritis and rheumatoid arthritis: relative validity of scales in relation to clinical measures of arthritis severity. Med Care 1999;37 Suppl:MS23-MS39.
25. Ware J Jr, Kosinski M, Gandek B. SF-36 Health Survey. Manual and interpretation guide. Lincoln, RI: QualityMetric Inc.; 2000.
26. EuroQo1 - A new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990;16:199-208.
27. Kobelt G, Andlin-Sobocki P, Maksymowych WP. The cost-effectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in Canada. J Rheumatol 2006;33:732-40.
28. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91.
29. van der Heijde D, Luo M, Matsumoto A, et al. Adalimumab improves health-related quality of life in patients with active ankylosing spondylitis - the ATLAS trial [abstract 490]. Arthritis Rheum 2005;52 Suppl:S211.
30. Braun J, Brandt J, Listing J, et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005;64:229-34.